{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "AVR",
  "name": "Anteris Technologies Global Corp.",
  "url": "https://orbyd.app/dossiers/AVR/",
  "json_url": "https://orbyd.app/dossiers/AVR.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "TAVR disruptor whose de-risking catalysts (CMS CED, first US patients, French ANSM clearance) are now exhausted; price faded ~11% off the ~$11.06 high back onto the in-the-money $250M ATM near $9. No 30-day data binary — PARADIGM readout is ~2028 — so the leg is price-led and maturing. Idiosyncratic, low-conviction watch.",
  "invalidation_trigger": "A weekly close below $9.00 loses the reclaimed TD Cowen ATM reference and the dilution shelf, confirming a failed breakout; secondary: an Appendix 4C or 8-K disclosing heavy ATM issuance into the fade, or any PARADIGM enrollment halt or safety signal.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Theme correction: AVR is a cardiovascular DEVICE (TAVR) story — prior 'oncology-immunology' / 'precision-therapeutics' tags are wrong.",
    "$250M TD Cowen/TD Securities ATM filed 2026-05-22 at $9.00 reference (~26-28M sh, ~27% of the ~97M count, 3.0% commission) = standing dilution ceiling, in-the-money above $9. Watch for 8-K/4C disclosure of heavy issuance.",
    "Real binary is ~2028 (PARADIGM 1-yr primary endpoint); enrollment completes ~Q1 2027 — NO tradeable data catalyst in 30d. The move to new highs is price-led, not narrative-led.",
    "Dual-listed ASX:AVR / NASDAQ:AVR — ASX session leads the US tape. Appendix 4C quarterly cash report (qtr ended 2026-06-30) due ~2026-07-31; watch ATM-draw pace and burn (~$28.7M/qtr Q1 outflow).",
    "Medtronic is BOTH a strategic investor (Covidien sub, up to $90M / 16-19.99% post-offering) AND the incumbent TAVR competitor — watch that dual relationship.",
    "Single-name momentum move, NOT a theme cluster — TAVR peers (EW, MDT, BSX) are mega-caps not breaking out together; no small-cap disruptor cohort confirming.",
    "Pre-revenue: 2025 net loss $94.14M on $1.91M revenue (-29% YoY); Q1 2026 EPS $(0.28) missed by a penny, sales $494K vs ~$767K est.",
    "Earnings blackout reminder: Q1 reported 2026-05-12; Q2 print ~mid-August 2026."
  ],
  "body_markdown": "## Current Thesis\n\nAnteris is a clinical-stage structural-heart company, dual-listed ASX:AVR / NASDAQ:AVR, built around DurAVR — a single-piece, 3D-shaped biomimetic transcatheter aortic valve now enrolling the US-pivotal PARADIGM trial (~1,000 patients, 1:1 versus commercial TAVR, non-inferiority composite of all-cause mortality, all stroke and CV hospitalization at one year). The de-risking sequence that powered the multi-quarter run is finished: CMS Coverage-with-Evidence-Development under NCD 20.32 (2026-04-28), first US patients at Montefiore (2026-05-05, Dr. Azeem Latib), and full French ANSM clearance (2026-06-08). Each moved enrollment forward without delivering trial data. Since the French clearance the tape has carried the story alone — price pushed to a fresh 52-week high near $11.06, then gave back roughly 11% to $9.77 by the July 10 close on no news, settling back onto the $9.00 TD Cowen ATM reference. Fifteen sessions later the picture is unchanged: no new narrative fuel, a live in-the-money $250M dilution shelf at the level price is retesting from above, and the real value inflection — PARADIGM's one-year endpoint — parked around 2028 with enrollment finishing ~Q1 2027. A genuine disruptor carrying Strong-Buy sell-side and ~64% of upside to the $16 average target, but the near-term move is price-led, not narrative-led. Maturing and idiosyncratic; a low-conviction watch that does not yet justify a fresh entry.\n\n## Bull Case\n\n- **Pivotal trial live and geographically broadening** — full French ANSM clearance (2026-06-08) opened recruitment at experienced French centers on top of active US/EU sites; first US patients treated 2026-05-05 (Montefiore, Dr. Latib). PARADIGM is ~1,000 patients, 1:1 DurAVR versus commercial TAVR, one-year non-inferiority composite.\n- **Reimbursement cleared before scale-up** — CMS Coverage-with-Evidence-Development under NCD 20.32 approved 2026-04-28; US site activation followed within a week, removing the largest US trial-execution risk ahead of the enrollment ramp.\n- **Incumbent strategic capital** — Covidien (Medtronic subsidiary) committed up to $90M for 16–19.99% of post-offering shares, closed 2026-01-22 alongside a $230M public raise ($320M aggregate). An incumbent funding a competing valve platform is a real endorsement.\n- **Sell-side leaning in** — consensus Strong/Moderate Buy, average PT $16.00 (~64% above the $9.77 close): Barclays Overweight PT $18 (2026-05-15), Wells Fargo Overweight PT $16 (2026-03-11), Cantor Overweight PT $15 (2026-03-27).\n- **Funded through enrollment** — the January raise plus the $250M ATM cover the ~$28.7M/qtr burn with no near-term financing cliff; market cap ~$951M as of 2026-07-10.\n\n## Bear Case\n\n- **The $250M ATM is an in-the-money seller into the fade.** TD Securities sales agreement dated 2026-05-22, up to $250M (~26–28M shares, ~27% of the ~97M count) at 3.0% commission. Above $9 the company can issue directly into strength — the facility manufactures supply at exactly the level the chart is now retesting from above.\n- **The momentum leg stalled with nothing behind it.** New high near $11.06, then ~11% back to $9.77 by 2026-07-10 on no news. CMS, first-patient and French clearance are complete and were enrollment-pace steps; the one-year binary sits around 2028 with enrollment finishing ~Q1 2027. No dated data catalyst inside 30 days.\n- **Pre-revenue with deep losses** — 2025 net loss $94.14M on $1.91M revenue (−29% YoY); Q1 2026 net cash outflow $28.7M ($17.5M to R&D), EPS $(0.28) missed by a penny, sales $494K vs ~$767K est. Any clinical hiccup is asymmetric downside.\n- **No peer cluster confirming.** TAVR incumbents Edwards Lifesciences, Medtronic and Boston Scientific are mega-caps that are range-bound, not breaking out together; there is no small-cap structural-heart disruptor cohort moving in sympathy. Strength is idiosyncratic and thin.\n- **Medtronic sits on both sides** — the Covidien stake sits beside Medtronic's incumbent TAVR franchise, so the relationship cuts both ways and could cap strategic optionality even as it validates the platform.\n\n## Setup & Price Structure\n\nThe 2026-06-08 French clearance marked the last narrative fuel; price extended to ~$11.06, a fresh 52-week high, then rolled over ~11% to $9.77 at the 2026-07-10 close ($9.99 after-hours) with no accompanying news. That fade dropped it straight onto the $9.00 TD Cowen ATM reference, a level that flips character with the tape: a reclaimed pivot while price holds above it, a supply ceiling the moment it cannot. Because the rally to new highs arrived without a catalyst, the whole read reduces to whether $9 holds on a closing basis. A break there returns price beneath the ATM strike and the dilution shelf and stamps the June–July high as a failed breakout; holding it keeps the reclaimed-pivot read alive but does not, on its own, create a reason to chase an extended single name with no near-term binary and no peers confirming. This is a name to let base rather than chase into a stalled, idiosyncratic leg.\n\n## Catalyst Calendar (next 30 days)\n\n- **No data readout in the window.** PARADIGM's one-year primary endpoint is ~2028 and enrollment completes ~Q1 2027. Interim enrollment or site-expansion press releases are possible but unscheduled.\n\n## Elapsed catalysts\n\n- **~2026-07-31 (est.)** — Appendix 4C quarterly cash-flow report (quarter ended 2026-06-30) on ASX. The key read is ATM-draw pace and cash burn against the ~$28.7M/qtr Q1 outflow; heavy issuance disclosed here would confirm the seller is active near $9. *(passed 9d ago)*\n- **~mid-August 2026 (est.)** — Q2 results (Q1 reported 2026-05-12). Pre-revenue print; the watch items are cash runway, R&D spend and PARADIGM enrollment commentary rather than the P&L lines. *(passed 89d ago)*\n\n## What Would Change Our Mind\n\nA weekly close below $9.00 loses the reclaimed TD Cowen ATM reference, puts price back under the dilution shelf, and confirms the June–July high as a failed breakout — that ends the constructive read. Secondary breaks: an 8-K or Appendix 4C disclosing heavy ATM issuance into the fade (supply arriving near $9), or any PARADIGM enrollment halt or safety signal. On the constructive side, the low-conviction stance would upgrade on a fresh dated catalyst — an interim enrollment milestone, a data-readout date pulled forward, or a structural-heart disruptor cluster breaking out together — that converts an idiosyncratic momentum name into a narrative with peers behind it.\n\n## Correlation Notes\n\nAVR trades on its own catalysts rather than as a theme vehicle. The TAVR reference set — Edwards Lifesciences, Medtronic, Boston Scientific — is mega-cap and range-bound, so the disruptor does not inherit a group bid, and there is no small-cap structural-heart cohort moving with it. The ASX:AVR session leads the US tape, so overnight Australian price action and the Appendix 4C filing set the US open. Medtronic is a dual node — strategic investor via Covidien and incumbent competitor — so Medtronic capital-markets or TAVR-franchise news can push AVR either way. Broad medtech-device beta and biotech risk appetite matter at the margin, but the dominant near-term driver is the ATM seller's behavior around $9.",
  "first_seen": "2026-05-24",
  "last_analyzed": "2026-07-26T11:50:38+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}